Millions of Americans battling obesity may soon gain access to weight-loss medications like Wegovy and Ozempic under Medicare or Medicaid, thanks to a proposed rule from the Biden administration. The initiative, spearheaded by the U.S. Department of Health and Human Services, aims to expand treatment options for obesity but faces potential roadblocks, including opposition from Robert F. Kennedy Jr., a vocal critic of these medications, who could block the proposal if confirmed as Secretary of Health and Human Services under a Trump administration.
Expanding Coverage for Obesity
If enacted, the rule would allow up to 7.5 million Medicare and Medicaid beneficiaries to access weekly injectable treatments for obesity, defined as having a BMI of 30 or higher. Currently, Medicare does not cover weight-loss drugs due to restrictions, although some recipients qualify under diabetes or heart disease risk. This proposal redefines obesity as a treatable medical condition, a significant shift in U.S. health policy.
Financial Implications
While the initiative could provide vital support for millions, its estimated $35 billion cost over the next decade has sparked debate among policymakers. Anti-obesity drugs like Wegovy, costing up to $1,300 per month, and Zepbound, priced at $1,000 monthly, highlight the financial challenge of expanding access to these treatments. The market for such drugs continues to grow, driven by FDA approval of new options that help individuals lose up to 25% of their body weight.
Opposition and Alternatives
Robert F. Kennedy Jr., a critic of weight-loss drugs, has advocated for alternatives such as government-subsidized healthy food programs and gym memberships. He argues these measures could provide long-term benefits at a similar cost while addressing obesity holistically. His stance underscores a broader debate over the best strategies to combat obesity in the U.S.
A Pivotal Moment for Health Policy
This proposal represents a critical moment in addressing obesity as a public health crisis. While it could transform care for millions, it also raises important questions about cost, accessibility, and the most effective ways to support Americans in managing their health.
